TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9145887
Drug: Teicoplanin 12
Normalized name: teicoplanin
DrugBank: Teicoplanin (DB06149)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teicoplanin 12 mg x kg(‐1) intravenously at induction of anesthesia
Study: 3129008
Drug: Captopril 12.5
Normalized name: captopril 12.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril 12.5 mg three times daily for 14 days
Study: 29844129
Drug: Binimetinib (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Binimetinib (30 mg twice a day continuous or 45 mg twice a day intermittent) with intravenous weekly paclitaxel (80 mg/m2)
Study: 29844129
Drug: Binimetinib (45
Approvals — FDA: no, EMA: no, PMDA: no
Description: Binimetinib (45 mg twice a day continuous)
Study: 29844129
Drug: Binimetinib (45
Approvals — FDA: no, EMA: no, PMDA: no
Description: Binimetinib (45 mg twice a day intermittent)
Study: 16563917
Drug: Tolvaptan (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolvaptan (10 mg/day, increased to 60 mg/day as needed)
Study: 16563917
Drug: Fluid restriction
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluid restriction (1,200 ml/day) plus placebo
Study: 12836579
Drug: Treatment mediation
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment mediation
Study: 9052581
Drug: Sublingual administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sublingual administration of micronized 17 beta-estradiol (1 mg, 0.5 mg, 0.25 mg)
Study: 9052581
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of micronized 17 beta-estradiol (1 mg, 0.5 mg)
Study: 20560941
Drug: Sublingual administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sublingual administration
Study: 8336809
Drug: Intra-arterial mannitol
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intra-arterial mannitol infusion (group A)
Study: 8336809
Drug: No intra-arterial
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: No intra-arterial mannitol infusion (group B)
Study: 27304433
Drug: 1.5 mg
Normalized name: boron 1.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg basimglurant MR
Study: 27304433
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg basimglurant MR
Study: 23547081
Drug: Gemcitabine (1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine (1,000 mg/m² on days 1, 8, and 15 of a 28-day cycle)
Study: 23547081
Drug: S-1 (80,
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-1 (80, 100, or 120 mg/d according to body-surface area on days 1 through 28 of a 42-day cycle)
Study: 23547081
Drug: Gemcitabine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine plus S-1 (gemcitabine 1,000 mg/m² on days 1 and 8 plus S-1 60, 80, or 100 mg/d according to body-surface area on days 1 through 14 of a 21-day cycle)
Study: 12601627
Drug: Daily multivitamin
Normalized name: DAILY MULTIVITAMIN TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily multivitamin therapy including 1 mg of folic acid for 4 weeks
Study: 12601627
Drug: Supplementation with
Normalized name: Similac For Supplementation with Iron Powder for Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplementation with 1 mg vitamin B(12) for an additional 4 weeks
Study: 12601627
Drug: High-dose vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose vitamin therapy (folic acid and vitamin B(12))
Study: 7832258
Drug: Paper diapers
Normalized name: Vanicream Diaper Rash
DrugBank: Dimethicone (DB11074)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Paper diapers containing absorbent gel material
Study: 90218
Drug: Prednisone 5
Normalized name: prednisone 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone 5 mg three times a day for 3-12 months
Study: 90218
Drug: Methylprednisolone 96
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone 96 mg/day for 7 days
Study: 22743678
Drug: Tralokinumab (150,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tralokinumab (150, 300 or 600 mg)
Study: 20824270
Drug: Dronabinol (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dronabinol (10 mg QID)
Study: 16009860
Drug: Parenteral anticoagulant
Normalized name: CPDA-1 Anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral anticoagulant agent or warfarin
Study: 16009860
Drug: Unfractionated or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unfractionated or low‐molecular‐weight heparin
Study: 16009860
Drug: Bridge therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bridge therapy (injectable anticoagulant agent plus warfarin)
Study: 10709504
Drug: Treatment-resistant periodontitis
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment-resistant periodontitis patients
Study: 10709504
Drug: Patients with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with severe marginal periodontitis who had responded to treatment
Study: 30860858
Drug: Asthma controller
Normalized name: epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Asthma controller medication adherence
Study: 17458427
Drug: Physician instruction
Normalized name: aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Physician instruction to use controller medication intermittently
Study: 17458427
Drug: Desire for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desire for control over treatment
Study: 11411906
Drug: 0.1% isotretinoin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% isotretinoin cream with chemical sunscreens
Study: 11411906
Drug: 4% benzoyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4% benzoyl peroxide cream
Study: 1211587
Drug: Topical analgesia
Normalized name: ANALGESIC TOP GEL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical analgesia using lignocaine applied to the pyriform fossae for superior laryngeal nerve block and topical analgesia of larynx and trachea.
Study: 31760855
Drug: Traditional six-month
Normalized name: moth bean extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional six-month follow-up programme with monthly calls (CON)
Study: 29673620
Drug: Acetaminophen 1000mg
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen 1000mg
Study: 28177706
Drug: BCAA (0.087
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCAA (0.087 g/kg body mass)
Study: 16540962
Drug: Povidone-iodine group
Normalized name: Povidone-Iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Povidone-iodine group (20 mL of a 10% povidone-iodine aqueous solution rinsing)
Study: 16540962
Drug: Saline group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline group (60 mL of saline solution rinsing)
Study: 10856105
Drug: Low-dose interferon
Normalized name: interferon-beta
DrugBank: Human interferon beta (DB14999)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose interferon alfa-2b (LDI) for 2 years
Study: 6142252
Drug: Towne strain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Towne strain cytomegalovirus (CMV) vaccine
Study: 28094472
Drug: Single-hormone artificial
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single-hormone artificial pancreas
Study: 28094472
Drug: Dual-hormone artificial
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dual-hormone artificial pancreas
Study: 24853314
Drug: Wound infiltration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wound infiltration (WI) with 1 mg·kg(‐1) 0.25% bupivacaine
Study: 24853314
Drug: Ultrasound-guided rectus
Normalized name: Sus scrofa rectum preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided rectus sheath block (USGRSB) with 0.5 mg·kg(‐1) 0.25% bupivacaine per side
Study: 22832531
Drug: Fortified balanced
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fortified balanced salt solution (BSS Plus)
Study: 9806648
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose chemoradiotherapy with 5-fluorouracil (5-FU) and mitomycin
Study: 9806648
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose chemoradiotherapy with 5-FU and mitomycin
Study: 7659873
Drug: Sodium bicarbonate‐trometamol‐phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium bicarbonate‐trometamol‐phosphate mixture (250 ml with buffering capacity 500 mmol/l)
Study: 7659873
Drug: 0.9% saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% saline (250 ml)
Study: 7659873
Drug: Buffer therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buffer therapy (sodium bicarbonate)
Study: 6118631
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg ergocalciferol (oral and intramuscular administration)
Study: 6118631
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg ergocalciferol (oral administration)
Study: 6118631
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg ergocalciferol (once a year regimen)
Study: 27629405
Drug: Personalised Hip
Normalized name: HIP
DrugBank: Heme iron polypeptide (DB11067)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Personalised Hip Therapy (PHT)
Study: 24829210
Drug: Deep-TMS treatment
Normalized name: Deep Sea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deep-TMS treatment (20 daily sessions at 20Hz, 120% MT)
Study: 17642239
Drug: Rituximab with
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab with concomitant MTX therapy
Study: 16313283
Drug: Tramadol 37.5
Normalized name: ACETAMINOPHEN 325MG/TRAMADOL 37.5MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol 37.5 mg/paracetamol 325 mg
Study: 16313283
Drug: Codeine 30
Normalized name: codeine 30 MG
DrugBank: Codeine (DB00318)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Codeine 30 mg/paracetamol 500 mg
Study: 31794027
Drug: mhGAP-based training
Approvals — FDA: no, EMA: no, PMDA: no
Description: mhGAP-based training (6 weeks, weekly sessions including lectures, discussions, role plays, and support sessions)
Study: 24708386
Drug: Treatment-as-usual (TAU)
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment-as-usual (TAU) condition (n = 126)
Study: 17566314
Drug: Amlodipine 10
Normalized name: amlodipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine 10 mg/day (monotherapy)
Study: 17566314
Drug: Amlodipine/benazepril 10/40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine/benazepril 10/40 mg/day and 10/20 mg/day
Study: 9186989
Drug: Long-term corticosteroid
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term corticosteroid treatment
Study: 3895381
Drug: Novaluzid (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Novaluzid (10 ml seven times daily)
Study: 25516019
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy (CBT), 10 sessions
Study: 22961466
Drug: Caregiving Stressors
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caregiving Stressors (daily care bother, behavioral bother, burden)
Study: 14501025
Drug: Cholesterol-lowering treatment
Normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholesterol-lowering treatment (statins)
Study: 8739113
Drug: L‐tryptophan (L‐TRP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L‐tryptophan (L‐TRP)
Study: 8739113
Drug: L‐TRP
Normalized name: L-TRP is the abbreviation for L-Tryptophan.
Approvals — FDA: no, EMA: no, PMDA: no
Description: L‐TRP
Study: 7034758
Drug: 0.5% bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% bupivacaine in 8% dextrose, 2 ml, 3 ml, or 4 ml
Study: 7034758
Drug: 0.75% bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.75% bupivacaine in 8% dextrose, 1.3 ml or 2 ml
Study: 7034758
Drug: 0.75% bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.75% bupivacaine in 8% dextrose, 3 ml
Study: 7034758
Drug: Both solutions
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both solutions (0.5% and 0.75%)
Study: 25136017
Drug: KAF156 single
Approvals — FDA: no, EMA: no, PMDA: no
Description: KAF156 single dose (10 to 1,200 mg)
Study: 25136017
Drug: KAF156 multiple
Approvals — FDA: no, EMA: no, PMDA: no
Description: KAF156 multiple doses (60 to 600 mg once daily for 3 days)
Study: 25136017
Drug: KAF156 (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: KAF156 (400 mg) under fed conditions
Study: 25136017
Drug: KAF156 (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: KAF156 (single and multiple doses)
Study: 20633284
Drug: Surfactant (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surfactant (200 mg/kg/dose, 3 doses at 0, 12, and 36 hours)
Study: 17438344
Drug: Care as
Normalized name: TopCare Aspirin 325mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Care as usual (family therapy or behavior therapy)
Study: 15677866
Drug: Donepezil (5.87
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donepezil (5.87 mg/day, SD = 1.92)
Study: 15677866
Drug: Galantamine (14.81
Approvals — FDA: no, EMA: no, PMDA: no
Description: Galantamine (14.81 mg/day, SD = 6.25)
Study: 15677866
Drug: Rivastigmine (6.41
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivastigmine (6.41 mg/day, SD = 1.82)
Study: 12797647
Drug: Valdecoxib 10
Normalized name: valdecoxib 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valdecoxib 10 mg once a day for 4 weeks
Study: 9583851
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose lipid (25-30% of total daily energy)
Study: 9583851
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose lipid (6-8% of total daily energy)
Study: 10327712
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of spraying plus housing improvement
Study: 6337038
Drug: heparin 5000
Normalized name: HEPARIN 5000 UNT/ML SYRINGE 1ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: heparin 5000
Study: 6337038
Drug: heparin 2500
Normalized name: heparin 2500 units/mL injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: heparin 2500
Study: 6337038
Drug: heparin 2500
Normalized name: heparin 2500 units/mL injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: heparin 2500 and 0.5 mg dihydroergotamine (HDHE 2500)
Study: 6337038
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg dihydroergotamine (DHE)
Study: 15193477
Drug: Aspirin 75
Normalized name: aspirin 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 75 mg daily from the day of embryo transfer until pregnancy test
Study: 10994153
Drug: myrtol standardized
Normalized name: myrtol
Approvals — FDA: no, EMA: no, PMDA: no
Description: myrtol standardized (4 x 300 mg, day 1‐14)
Study: 10994153
Drug: cefuroxime (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: cefuroxime (2 x 250 mg daily for day 1‐6)
Study: 10994153
Drug: ambroxol (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: ambroxol (3 x 30 mg for day 1‐3, 2 x 30 mg for days 4‐14)
Study: 30210070
Drug: MitraClip (MC)
Normalized name: MC-3
Approvals — FDA: no, EMA: no, PMDA: no
Description: MitraClip (MC) treatment
Study: 24343788
Drug: Operated knees
Normalized name: Bos taurus knee joint preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Operated knees (T2 values of suprapatellar subcutaneous adipose tissue)
Study: 24343788
Drug: Control knees
Normalized name: Bos taurus knee joint preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control knees (T2 values of suprapatellar subcutaneous adipose tissue)
Study: 22732113
Drug: Single-lumen tracheal
Normalized name: Luden's
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-lumen tracheal tube with Arndt® blocker
Study: 17585665
Drug: Chinese herbs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese herbs with modified Buzhong Yiqi Decoction, one dose each day, 10 doses per course.
Study: 17585665
Drug: Western medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medicine with bandazol, Dextran 40, Danshen tablet, and vitamin B12, 10 days per course.
Study: 12167139
Drug: Amitriptyline combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline combined with fluoxetine (group 2)
Study: 10209075
Drug: Lisinopril, 20
Normalized name: Lisinopril, 20 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril, 20 mg/day (n=20)
Study: 9456943
Drug: Manual injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual injection at 2 ml/sec (Group 1)
Study: 9456943
Drug: Automatic injection
Normalized name: AMMONIA,AROMATIC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Automatic injection at 2 ml/sec (Group 3)
Study: 9456943
Drug: Automatic injection
Normalized name: AMMONIA,AROMATIC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Automatic injection at 4 ml/sec (Group 4)
Study: 9456943
Drug: Automatic injection
Normalized name: AMMONIA,AROMATIC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Automatic injection at 6 ml/sec (Group 5)
Study: 31141198
Drug: Immediate loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate loading of two implants supporting a locator-retained mandibular overdenture
Study: 31141198
Drug: Delayed loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed loading of two implants supporting a locator-retained mandibular overdenture
Study: 25832995
Drug: Low-dose (0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose (0.6 mg/kg body weight; maximum 60 mg) i.v. rt-PA
Study: 25832995
Drug: Standard-dose (0.9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose (0.9 mg/kg body weight; maximum 90 mg) i.v. rt-PA
Study: 23525080
Drug: Non-viral, liposome-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-viral, liposome-based gene therapy formulation
Study: 21457152
Drug: Sildenafil (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil (0.5 mg.kg(‐1))
Study: 17110217
Drug: Dutasteride 0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dutasteride 0.05 mg
Study: 17110217
Drug: Dutasteride 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dutasteride 0.1 mg
Study: 11316141
Drug: Celecoxib 200
Normalized name: celecoxib 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib 200 mg b.i.d.
Study: 8187254
Drug: Intravenous group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous group
Study: 30122896
Drug: Leucostim® (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leucostim® (5 μg/kg)
Study: 30122896
Drug: Leucostim® (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leucostim® (10 μg/kg)
Study: 30122896
Drug: Neupogen® (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neupogen® (5 μg/kg)
Study: 30122896
Drug: Neupogen® (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neupogen® (10 μg/kg)
Study: 18663723
Drug: Darifenacin 7.5/15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Darifenacin 7.5/15 mg once daily (o.d.)
Study: 12182381
Drug: M-M-R II
Normalized name: M-M-R II
DrugBank: Rubella virus vaccine (DB10317)
Approvals — FDA: no, EMA: no, PMDA: no
Description: M-M-R II and VARIVAX administered 6 weeks apart (Group B)
Study: 8575573
Drug: Inhaled beclomethasone
Normalized name: beclomethasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled beclomethasone dipropionate (BDP) 200 micrograms b.i.d. for 3 months
Study: 375881
Drug: Penicillamine treatment
Normalized name: Penicillamine
DrugBank: Penicillamine (DB00859)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Penicillamine treatment (250 mg, 3 capsules per day)
Study: 375881
Drug: Placebo (lactose,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (lactose, 3 capsules per day)
Study: 28633675
Drug: Jiao's scalp
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jiao's scalp acupuncture combined with conventional rehabilitation treatment
Study: 26426042
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg intramuscular phylloquinone
Study: 26426042
Drug: 0.2 mg
Normalized name: niacin 0.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg intramuscular phylloquinone
Study: 26426042
Drug: 0.2 mg
Normalized name: niacin 0.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg intravenous phylloquinone
Study: 26426042
Drug: Bolus dose
Normalized name: SET,INFUSION,BOLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus dose of phylloquinone at birth
Study: 23110811
Drug: Preoperative chemotherapy
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative chemotherapy (CT) with epirubicin 120 mg/m² and ifosfamide 9 g/m² followed by two postoperative cycles
Study: 23110811
Drug: Preoperative chemotherapy
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative chemotherapy (CT) with radiotherapy (RT)
Study: 20963831
Drug: Tobramycin inhalation
Normalized name: Tobramycin Inhalation Powder
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tobramycin inhalation powder (112 mg, twice daily)
Study: 20963831
Drug: Tobramycin inhalation
Normalized name: Tobramycin Inhalation Powder
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tobramycin inhalation powder
Study: 19197779
Drug: Web-based course
Approvals — FDA: no, EMA: no, PMDA: no
Description: Web-based course on cognitive behavioral therapy (CBT)
Study: 15589109
Drug: Single oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of galantamine (GAL)
Study: 11064501
Drug: Triple antiretroviral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple antiretroviral therapy (two nucleoside reverse transcriptase inhibitors (NRTIs) plus one protease inhibitor)
Study: 11064501
Drug: Double therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double therapy (two NRTIs)
Study: 11064501
Drug: Double therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double therapy and Triple therapy
Study: 8144850
Drug: Goserelin depot
Approvals — FDA: no, EMA: no, PMDA: no
Description: Goserelin depot formulation 3.6 mg every 28 days for 6 months (first implant in early follicular phase)